Ucci Argia, Rucci Nadia, Ponzetti Marco
Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila 67100, Italy.
Cancer Drug Resist. 2022 Jun 21;5(3):541-559. doi: 10.20517/cdr.2022.17. eCollection 2022.
Liquid biopsies are a powerful tool to non-invasively analyze tumor phenotype and progression as well as drug resistance. In the bone oncology field, liquid biopsies would be particularly important to develop, since standard biopsies can be very painful, dangerous (e.g., when found in proximity to the spinal cord), and hard to collect. In this review, we explore the recent advances in liquid biopsies in both primary (osteosarcoma and Ewing sarcoma) and secondary bone cancers (breast, prostate, and lung cancer-induced bone metastases), presenting their current role and highlighting their unexpressed potential, as well as the barriers limiting their possible adoption, including costs, scalability, reproducibility, and isolation methods. We discuss the use of circulating tumor cells, cell-free circulating tumor DNA, and extracellular vesicles for the purpose of improving diagnosis, prognosis, evaluation of therapy resistance, and driving therapy decisions in both primary and secondary bone malignancies.
液体活检是一种用于非侵入性分析肿瘤表型、进展以及耐药性的强大工具。在骨肿瘤领域，开发液体活检尤为重要，因为标准活检可能非常痛苦、危险（例如，当靠近脊髓时）且难以采集。在本综述中，我们探讨了液体活检在原发性（骨肉瘤和尤因肉瘤）和继发性骨癌（乳腺癌、前列腺癌和肺癌引起的骨转移）方面的最新进展，介绍了它们目前的作用，强调了它们尚未发挥的潜力，以及限制其可能应用的障碍，包括成本、可扩展性、可重复性和分离方法。我们讨论了循环肿瘤细胞、游离循环肿瘤DNA和细胞外囊泡在改善原发性和继发性骨恶性肿瘤的诊断、预后、治疗耐药性评估以及指导治疗决策方面的应用。
